肾上腺髓质素系统失调预测ACS患者心源性休克与死亡风险
该研究纳入瑞士SPUM-ACS队列4098例和法国FAST-MI队列824例入院时无休克的急性冠脉综合征患者,检测ADM-Gly、PAM和bio-ADM。结果显示,ADM-Gly和bio-ADM可独立预测院内CS和1年死亡风险,并在ORBI评分基础上改善早期风险分层,而PAM无此预测价值。
要点
- ADM-Gly和bio-ADM升高与ACS后院内CS及1年死亡风险独立相关
- 将ADM-Gly和bio-ADM加入ORBI评分可改善CS风险判别与重分类
- PAM未显示对CS或死亡风险的独立预测价值
核心结论
- ADM-Gly和bio-ADM可独立预测入院时稳定的ACS患者院内CS和1年死亡风险,并改善早期危险分层。
研究设计与样本
- 前瞻性队列研究,纳入瑞士SPUM-ACS队列4098例和法国FAST-MI队列824例入院时无CS的ACS患者。
- 检测ADM-Gly、PAM和bio-ADM,主要终点为院内CS,次要终点为1年死亡,采用多变量校正回归分析。
主要发现
- ADM-Gly和bio-ADM升高与全身炎症及血流动力学受损相关,PAM则无此关联。
- ADM-Gly和bio-ADM在瑞士队列中独立预测CS风险,每log2升高aOR分别为1.44(95%CI 1.22-1.71,P<.001)和1.37(95%CI 1.10-1.70,P=.004)。
- 法国队列中ADM-Gly和bio-ADM预测CS的aRR为1.82(95%CI 1.34-2.48,P<.001)和1.55(95%CI 1.15-2.10,P=.004)。
- ADM-Gly和bio-ADM与1年死亡风险相关,aHR分别为1.33(95%CI 1.09-1.61,P=.005)和1.46(95%CI 1.15-1.86,P=.002)。
关键数值与推荐
- 在ORBI评分基础上加入ADM-Gly和bio-ADM后,曲线下面积增加0.02,净重分类改善为0.229,AIC降低26.9。
临床怎么用
- 对入院时血流动力学稳定的ACS患者,检测ADM-Gly和bio-ADM有助于更早识别院内CS高危人群。
- 可在传统风险评分基础上联合ADM-Gly和bio-ADM进行风险再分层,指导监护强度和早期干预决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Cardiogenic shock (CS) is the most dreadful complication of acute coronary syndromes (ACS). Endothelial dysfunction and vascular leakage are hallmarks of CS pathophysiology; however, biomarkers reflecting these early processes are lacking. The adrenomedullin (ADM) system-the inactive precursor glycine-extended ADM (ADM-Gly), the activating enzyme peptidylglycine α-amidating monooxygenase (PAM), and biologically active ADM (bio-ADM)-modulates vascular tone and permeability. This study investigated associations of ADM system components with CS and 1-year mortality risk after ACS. METHODS: ADM-Gly, PAM, and bio-ADM were assessed in 4098 (Switzerland; SPUM-ACS) and 824 (France; FAST-MI) ACS patients without CS on admission. The primary endpoint was in-hospital CS; the secondary endpoint was 1-year mortality. Biomarker-outcome associations were analysed using multivariable-adjusted regression models, and the incremental predictive value beyond established risk scores was quantified. RESULTS: Higher ADM-Gly and bio-ADM, but not PAM, were associated with systemic inflammation and haemodynamic compromise. ADM-Gly and bio-ADM independently predicted CS risk in Switzerland (adjusted odds ratio [aOR] per log2 increase, 1.44, 95% confidence interval [CI] 1.22-1.71, P < .001 and aOR 1.37, 95% CI 1.10-1.70, P = .004) and France (adjusted risk ratio [RR] per log2 increase, 1.82, 95% CI 1.34-2.48, P < .001 and aRR 1.55, 95% CI 1.15-2.10, P = .004), and were associated with 1-year mortality risk (adjusted hazard ratio [aHR] per log2 increase, 1.33, 95% CI 1.09-1.61, P = .005 and aHR 1.46, 95% CI 1.15-1.86, P = .002). Addition of ADM-Gly and bio-ADM to the ORBI risk score improved its discrimination (Δ area under the receiver operating characteristic curve 0.02), reclassification (net reclassification improvement 0.229), and model fit (Δ Akaike information criterion -26.9), with consistent results in external validation. CONCLUSIONS: ADM-Gly and bio-ADM, but not PAM, independently predict in-hospital CS and 1-year mortality risk in initially stable patients with ACS and improve early risk stratification.
引用
- Wang, Danchin, Simon, et al. Adrenomedullin system dysregulation predicts cardiogenic shock and mortality in acute coronary syndromes. Eur Heart J. 2026. PMID: 42668424. doi:10.1093/eurheartj/ehag636
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。